Insmed Inc. has identified new cathepsin C (dipeptidyl peptidase I; DPP1) inhibitors potentially useful for the treatment of cancer, inflammatory bowel disease, bronchiectasis, asthma, cystic fibrosis, lupus nephritis, pulmonary hypertension and rheumatoid arthritis.
HK Inno.N Corp. has disclosed new 5-cyclopropylpicolinamide derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors potentially useful for the treatment of cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has detailed the discovery and preclinical characterization of ZMS-2195, a multiple-RAS inhibitor designed to prevent both mutant and wild-type forms of KRAS, NRAS and HRAS from binding to the RAS-binding domain (RBD) of RAF, which is required to activate downstream MAPK signaling.
Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatment of cancer.
Beijing Innocare Pharma Tech Co. Ltd. has received IND approval from China’s National Medical Products Administration (NMPA) for ICP-B208, an antibody-drug conjugate targeting CDH17, which is highly expressed in gastrointestinal cancers, including colorectal, gastric and biliary tract cancers and pancreatic ductal adenocarcinoma.
UCB SA has entered into a new multiproject strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, to advance a pipeline of novel investigational oncology candidates.
A joint Nankai University and Tianjin Accendatech Technology Co. Ltd. patent describes new isoalantolactone derivatives reported to be useful for the treatment of liver cancer.
Solve Therapeutics Inc. has prepared and tested new antibody-drug conjugates (ADCs) comprising a monoclonal antibody targeting trophoblast glycoprotein (TPBG; 5T4) covalently linked to cytotoxic drug and reported to be useful for the treatment of cancer.
RSS
